Coronavirus: Russian Sputnik V vaccine shows 91.6% effectiveness in phase 3 trial

Get real time updates directly on you device, subscribe now.

The Sputnik V coronavirus vaccine developed in Russia showed a 91.6% effectiveness rate in the phase 3 trial, Reuters reported Tuesday, citing data published by The Lancet.

The publication further showed that there were no serious adverse events associated with the vaccine, which was equally effective in people older than 60 years.

.

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.